In non-ALCL, single-agent BV showed clinical antitumor activity in AITL and PTCL-NOS, with ORR of 41% (including 54% ORR in AITL with a median PFS of 6.7 months), although responses did not correlate with CD30 expression [16]. The gene discussed is TNFRSF8; the disease is angioimmunoblastic T-cell lymphoma.